Cargando…

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus

INTRODUCTION: Immune checkpoint inhibitors (ICI) produce dramatic tumor shrinkage and durable responses in many advanced malignancies, but their use is limited by the development of immune-related adverse events (IRAEs) that occur in up to 60% of patients and often affect endocrine organs. Concern f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hilder, Robin, Tsai, Karen, Quandt, Zoe, Isaacs, Dayna, Drakaki, Alexandra, Xing, Yan, In, Gino K., Angell, Trevor E., Lechner, Melissa G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643762/ https://www.ncbi.nlm.nih.gov/pubmed/38027216 http://dx.doi.org/10.3389/fendo.2023.1242830

Ejemplares similares

THU299 Safety Of Immune Checkpoint Inhibitor Cancer Therapy In Patients With Pre-existing Type 1 Diabetes Mellitus: A Multi-Center Cohort Study
por: Hilder, Robin, et al.
Publicado: (2023)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2023)

Identification of RORg(+)T Cells as Key Players in Thyroid Autoimmunity From Checkpoint Immunotherapy
por: Lechner, Melissa G, et al.
Publicado: (2021)

Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial fibrillation: A meta-analysis
por: Xu, Juan, et al.
Publicado: (2022)

SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus
por: Quandt, Zoe, et al.
Publicado: (2020)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor–Induced Thyroiditis
por: Chen, Dennis H., et al.
Publicado: (2023)

Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin
por: Do, Nicoline Callesen, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2020)

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
por: Hui, Gavin, et al.
Publicado: (2023)

Editorial: Influence of sleep and recurrent circadian disruption on cardiometabolic health, wellbeing, and safety: from shiftwork to Monday mornings
por: Cheng, Philip, et al.
Publicado: (2023)

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
por: Coureau, Michelle, et al.
Publicado: (2020)

Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment
por: Ahmadi, Sara, et al.
Publicado: (2022)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

SAT036 Chlorthalidone Implicated In The Development Of DKA HHS Overlap In A Patient With Type II Diabetes Mellitus
por: Hilder, Robin T
Publicado: (2023)

Outcomes of preexisting diabetes mellitus in breast, colorectal, and prostate cancer
por: Griffiths, Robert I., et al.
Publicado: (2017)

Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM
por: Zhang, Wenjing, et al.
Publicado: (2023)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
por: John, Mathew, et al.
Publicado: (2016)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Preexisting Type 1 Diabetes Mellitus Blunts the Development of Posttraumatic Osteoarthritis
por: Rios‐Arce, Naiomy D, et al.
Publicado: (2022)

Risk of acute epiglottitis in patients with preexisting diabetes mellitus: A population-based case–control study
por: Tsai, Yao-Te, et al.
Publicado: (2018)

The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis
por: Tang, Qizhi, et al.
Publicado: (2022)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022)

Endocrine side effects of immune checkpoint inhibitors
por: Cardona, Zulma, et al.
Publicado: (2023)

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials
por: Zhou, Feifei, et al.
Publicado: (2022)

Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus
por: Guo, Xinyang, et al.
Publicado: (2023)

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
por: Zhang, Dongming, et al.
Publicado: (2022)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

COVID-19 vaccine coverage, safety, and perceptions among patients with diabetes mellitus in China: a cross-sectional study
por: Li, Haolong, et al.
Publicado: (2023)

Mouse models of preeclampsia with preexisting comorbidities
por: Waker, Christopher A., et al.
Publicado: (2023)

Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
por: Corrao, Salvatore, et al.
Publicado: (2021)

Association Between Obesity and Microvascular Diseases in Patients With Type 2 Diabetes Mellitus
por: Gao, Shan, et al.
Publicado: (2021)

Obesity is associated with greater cognitive function in patients with type 2 diabetes mellitus
por: Xing, Zhenhua, et al.
Publicado: (2022)

Incidence and Risk Factors of Gestational Diabetes Mellitus: A Prospective Cohort Study in Qingdao, China
por: Li, Guoju, et al.
Publicado: (2020)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

Increased mortality for colorectal cancer patients with preexisting diabetes mellitus: an updated meta-analysis
por: Li, Jingtao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qnrqap9p4nr7abv6t1ndif8n9t